全文获取类型
收费全文 | 2940816篇 |
免费 | 233087篇 |
国内免费 | 5882篇 |
专业分类
耳鼻咽喉 | 42594篇 |
儿科学 | 91349篇 |
妇产科学 | 80669篇 |
基础医学 | 414008篇 |
口腔科学 | 84000篇 |
临床医学 | 264089篇 |
内科学 | 577369篇 |
皮肤病学 | 60426篇 |
神经病学 | 245433篇 |
特种医学 | 117867篇 |
外国民族医学 | 1129篇 |
外科学 | 449425篇 |
综合类 | 68531篇 |
现状与发展 | 1篇 |
一般理论 | 1170篇 |
预防医学 | 233509篇 |
眼科学 | 69316篇 |
药学 | 218539篇 |
4篇 | |
中国医学 | 5548篇 |
肿瘤学 | 154809篇 |
出版年
2018年 | 29967篇 |
2016年 | 25515篇 |
2015年 | 28842篇 |
2014年 | 41558篇 |
2013年 | 63495篇 |
2012年 | 85527篇 |
2011年 | 90334篇 |
2010年 | 53577篇 |
2009年 | 51432篇 |
2008年 | 86076篇 |
2007年 | 91390篇 |
2006年 | 92256篇 |
2005年 | 90086篇 |
2004年 | 86563篇 |
2003年 | 83732篇 |
2002年 | 82544篇 |
2001年 | 135253篇 |
2000年 | 139601篇 |
1999年 | 118263篇 |
1998年 | 34100篇 |
1997年 | 31062篇 |
1996年 | 30834篇 |
1995年 | 29615篇 |
1994年 | 27830篇 |
1993年 | 26038篇 |
1992年 | 94855篇 |
1991年 | 91523篇 |
1990年 | 88556篇 |
1989年 | 85355篇 |
1988年 | 79382篇 |
1987年 | 78140篇 |
1986年 | 74365篇 |
1985年 | 70872篇 |
1984年 | 53590篇 |
1983年 | 45735篇 |
1982年 | 27943篇 |
1981年 | 24732篇 |
1980年 | 23303篇 |
1979年 | 50265篇 |
1978年 | 35257篇 |
1977年 | 29867篇 |
1976年 | 28036篇 |
1975年 | 29785篇 |
1974年 | 36471篇 |
1973年 | 34699篇 |
1972年 | 32608篇 |
1971年 | 30127篇 |
1970年 | 28515篇 |
1969年 | 26608篇 |
1968年 | 24530篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
131.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
132.
133.
Changhyun Kim B.S. Brittany G. Craiglow M.D. Kalman L. Watsky M.D. Richard J. Antaya M.D. 《Pediatric dermatology》2015,32(4):e161-e162
A 17‐year‐old boy presented with recurring severe dermatitis of the face of 5‐months duration that resembled impetigo. He had been treated with several courses of antibiotics without improvement. Biopsy showed changes consistent with allergic contact dermatitis and patch testing later revealed sensitization to benzoyl peroxide, which the patient had been using for the treatment of acne vulgaris. 相似文献
134.
A case of bullous pemphigoid associated with psoriasis vulgaris showing Hailey–Hailey disease‐like histopathological changes in regenerated epidermis without genomic mutation in ATP2C1 or ATP2A2 gene
下载免费PDF全文
![点击此处可从《Journal of the European Academy of Dermatology and Venereology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
135.
F. Fruzzetti G. Palla A. Sbrana T. Simoncini M. R. Sessa 《Gynecological endocrinology》2020,36(10):938-940
AbstractObjective: To understand the origin of extremely high gonadotropin levels in a perimenopausal woman.Methods: A 52-year-old woman with a 2?months of amenorrhea followed spontaneous menstrual cycles recovery was referred to our outpatient clinic with elevated follicle-stimulating hormone (FSH, 483 mUI/ml), luteinizing hormone (LH, 475 mUI/ml) and prolactin (PRL, 173?ng/ml). She was known to take levosulpiride. The gonadotropin levels did not fit with the clinical features.Results: A gonadotroph tumor was ruled out. Further analysis confirmed constantly high FSH, LH and PRL levels. The measurements were repeated using different analytical platforms with different results. After serial dilutions, nonlinearity was present suggesting an immunoassay interference. After post-polyethylene glycol recovery, hormone levels appeared in the normal range. Anti-goat antibodies were recognized in the serum of the patient.Conclusions: This case report shows a case of falsely abnormal high gonadotropin and PRL levels in a woman during menopause transition. In the clinical practice the evaluation of gonadotropin profile is not recommended at this age, but the abnormal levels stimulated further evaluation. An interference in the assay due to anti-goat antibodies resulted in abnormally high level of FSH and LH. A strict collaboration between clinicians and the laboratory is needed, when laboratory findings do not correspond to clinical findings. 相似文献
136.
137.
T. Wu L. G. Trahair M. J. Bound C. F. Deacon M. Horowitz C. K. Rayner K. L. Jones 《Diabetic medicine》2015,32(5):595-600
138.
Martin F. Shapiro 《Journal of general internal medicine》2015,30(10):1392-1393
139.
140.